Clinical Trial Update: Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors [EARLY_Phase 1]

View source ↗

Summary

An EARLY Phase 1 clinical trial of Gallium-68 Pentixafor for neuroendocrine tumors is listed as active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Gallium-68 Pentixafor (pentixafor (68Ga-labeled radiopharmaceutical))

Snippet

Sponsor: Yusuf Menda | Conditions: Neuroendocrine Tumors | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING